Document is current
Any future updates will be listed below
-
Authors
Xing, Fei-fei
Wang, Dan-yang
Xu, Yan-nan
Zheng, Xin-rui
Zhang, Shi-hao
Zong, Meng-yao
Zhan, Jun-yi
Wang, De-xin
Liu, Wei
Chen, Jia-mei
Chen, Gao-feng
Liu, Ping
Liu, Cheng-hai
Mu, Yong-ping
-
Funding
Funding for this research was provided by:
Science and Technology Innovation Plan Of Shanghai Science and Technology Commission (22S11901700)
Natural Science Foundation of Shanghai Municipality (21ZR1464100)
National Natural Science Foundation of China (81874390)
- License Information
-
More Information
Article History
Received: 10 June 2025
Accepted: 18 August 2025
First Online: 30 August 2025
Declarations
:
: Liver tissue slices from patients with hepatitis B-associated liver fibrosis were obtained from the biobank of the clinical study titled “Chinese Herbal Medicine Combined with Entecavir in Treating Hepatitis B Cirrhosis”. This clinical trial was approved by the Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of TCM (Ethics approval No. 2014-331-27-01). The ethics of animal experimentation are as follows: (1) Title of the approved project: The effector mechanism of macrophage polarization in the regulation of hepatic progenitor cells differentiation and intervention in liver cirrhosis. (2) Name of the institutional approval committee or unit: Animal Research Committee at Shanghai University of TCM. (3) Ethics approval No. PZSHUTCM210611009. (4) Date of approval: June 11, 2021.
: Not applicable.
: The authors declare that they have no competing interests.
